Summary
Global Markets Direct’s, ‘Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2016’, provides in depth analysis on Hepatitis C Virus Envelope Protein E2 targeted pipeline therapeutics.
The report provides comprehensive information on the Hepatitis C Virus Envelope Protein E2 , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
- The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Aviragen Therapeutics, Inc.
Integrated BioTherapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatitis C Virus Envelope Protein E2 Overview 6
Therapeutics Development 7
Hepatitis C Virus Envelope Protein E2 - Products under Development by Stage of Development 7
Hepatitis C Virus Envelope Protein E2 - Products under Development by Therapy Area 8
Hepatitis C Virus Envelope Protein E2 - Products under Development by Indication 9
Hepatitis C Virus Envelope Protein E2 - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Hepatitis C Virus Envelope Protein E2 - Products under Development by Companies 12
Hepatitis C Virus Envelope Protein E2 - Products under Development by Universities/Institutes 14
Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development 22
Aviragen Therapeutics, Inc. 22
Integrated BioTherapeutics, Inc. 23
Hepatitis C Virus Envelope Protein E2 - Drug Profiles 24
BTA-074 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
CIGB-230 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
E-137 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
E-20 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
hepatitis C (strain H77) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
hepatitis C (virus-like particle) vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
MBL-HCV-1 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Monoclonal Antibody to Target E2 for Hepatitis C - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Hepatitis C Virus Envelope Protein E2 - Dormant Projects 36
Hepatitis C Virus Envelope Protein E2 - Discontinued Products 37
Hepatitis C Virus Envelope Protein E2 - Featured News & Press Releases 38
Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma 38
Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released 38
Jun 10, 2013: IBT and Stanford Awarded STTR 39
Aug 30, 2012: Researchers Develop Monoclonal Antibody That Prevents Hepatitis C In Animal Model 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42
List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Aviragen Therapeutics, Inc., H2 2016 22
Pipeline by Integrated BioTherapeutics, Inc., H2 2016 23
Dormant Projects, H2 2016 36
Discontinued Products, H2 2016 37
List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Molecule Types, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 20
